• Home
  • News
  • UCI statement concerning Marcin Polak

UCI statement concerning Marcin Polak

UCI Logo
The Union Cycliste Internationale (UCI) announces that the polish para-cyclist Marcin Polak has been sanctioned with a period of ineligibility of four (4) years following an Anti-Doping Rule Violation (ADRV) for the presence of Erythropoietin (EPO)[1] in three samples[2] collected on 19 May, 31 July and 2 August 2021.

In accordance with the World Anti-Doping Code (the Code) and the UCI Anti-Doping Regulations (UCI ADR), the period of ineligibility started on 27 August 2021 and is effective until 26 August 2025 (included).

The results obtained by the rider in between 19 May 2021 and 27 August 2021 have been disqualified.

The case has been resolved by way of an acceptance of consequences as provided for by the Code and the UCI ADR.

The UCI will not comment any further.

[1] Erythropoietin (EPO) is a Prohibited Substance listed under class S2.1 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of the 2021 Prohibited List which is maintained by the World Anti-Doping Agency (WADA) and adopted by the UCI.

[2] The UCI took over the results management related to the samples collected by the Polish National Anti-Doping Agency on 19 May and 31 July 2021.

The original press release can be found here :https://www.uci.org/pressrelease/uci-statement-concerning-marcin-polak-30-may-2022/1S9NQStJXPc3RKVb5eez3m

Leave a comment

Please login to leave a comment.


Legal Advisors

Copyright © LawInSport Limited 2010 - 2022. These pages contain general information only. Nothing in these pages constitutes legal advice. You should consult a suitably qualified lawyer on any specific legal problem or matter. The information provided here was accurate as of the day it was posted; however, the law may have changed since that date. This information is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. LawInSport is not responsible for any actions taken or not taken on the basis of this information. Please refer to the full terms and conditions on our website.